AIT Therapeutics (OTCMKTS:AITB) Downgraded by Zacks Investment Research to “Sell”

Zacks Investment Research cut shares of AIT Therapeutics (OTCMKTS:AITB) from a hold rating to a sell rating in a research report report published on Friday, reports.

According to Zacks, “AIT Therapeutics, Inc. is a clinical-stage anti-microbial therapeutic company using nitric oxide to treat respiratory and other diseases. The Company is currently applying its therapeutic expertise to treat lower respiratory tract infections, which are not effectively addressed with current standards of care. It is advancing its revolutionary respiratory targeted system in clinical trials for the treatment of bronchiolitis and nontuberculous mycobacteria. AIT Therapeutics, Inc. is based in Ness Ziona, Israel. “

Separately, ValuEngine upgraded AIT Therapeutics from a hold rating to a buy rating in a research note on Friday, March 1st.

Shares of OTCMKTS AITB opened at $5.55 on Friday. The company has a market capitalization of $46.25 million, a price-to-earnings ratio of -1.84 and a beta of -0.31. AIT Therapeutics has a 1-year low of $3.11 and a 1-year high of $6.25. The business’s 50 day moving average price is $5.28.

AIT Therapeutics Company Profile

AIT Therapeutics, Inc, a clinical-stage medical device and biopharmaceutical company, develops nitric oxide (NO) delivery systems to treat respiratory and other diseases. Its NO delivery systems are used for the treatment of pulmonary hypertension of the newborn, bronchiolitis, and nontuberculous mycobacteria.

Featured Story: Understanding Stock Ratings

Get a free copy of the Zacks research report on AIT Therapeutics (AITB)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for AIT Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AIT Therapeutics and related companies with's FREE daily email newsletter.